PD-1 and PD-L1 Inhibitors Commpetitive Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Compass

The PD-1 and PD-L1 Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“PD-1 and PD-L1 Inhibitors Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 and PD-L1 Inhibitors Market.

Some of the key takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report: 

• Companies across the globe are diligently working toward developing novel PD-1 and PD-L1 Inhibitors treatment therapies with a considerable amount of success over the years. 
• PD-1 and PD-L1 Inhibitors companies working in the treatment market are Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others, are developing therapies for the PD-1 and PD-L1 Inhibitors treatment 

• Emerging PD-1 and PD-L1 Inhibitors therapies such as – CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others are expected to have a significant impact on the PD-1 and PD-L1 Inhibitors market in the coming years.   
• In February 2023, Merck Sharp & Dohme LLC initiated a trial titled, “An Open-label, Multicenter, Phase3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)”
• In April 2023, Merck announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’santi-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response
• In January 2022 European approval for renal cell carcinoma was based on data from KEYNOTE-564 (NCT03142334), a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 994 patients with increased risk of recurrence of RCC defined as intermediate-high or high risk, or M1 with no evidence of disease (NED)
• In January 2022, Gilead Sciences, Inc. announced it has entered into two clinical trial collaboration and supply agreements with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of Gilead’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy) and Merck’s anti-PD-1therapy KEYTRUDA® (pembrolizumab) in first-line metastatic non-small cell lung cancer (NSCLC)

PD-1 and PD-L1 Inhibitors Overview

PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells and eliminate them before they can turn into cancer

Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape

Emerging PD-1 and PD-L1 Inhibitors Drugs Under Different Phases of Clinical Development Include:

• CTX-8371: Compass Therapeutics
• CA 327: Aurigene Discovery Technologies
• RC-98: RemeGen
• AUR-106: Aurigene Discovery Technologies
• INBRX 105: Inhibrx
• Tomivosertib: Effector Therapeutics
• CX-072: CytomX Therapeutics
• IBI 323: Innovent Biologics
• Jemperli: GlaxoSmithKline
• BCD-100: Biocad
• TECENTRIQ: Genentech
• Opdivo: Bristol Myers Squibb
• KEYTRUDA: Merck

PD-1 and PD-L1 Inhibitors Pipeline Therapeutics Assessment

• PD-1 and PD-L1 Inhibitors Assessment by Product Type
• PD-1 and PD-L1 Inhibitors By Stage and Product Type
• PD-1 and PD-L1 Inhibitors Assessment by Route of Administration
• PD-1 and PD-L1 Inhibitors By Stage and Route of Administration
• PD-1 and PD-L1 Inhibitors Assessment by Molecule Type
• PD-1 and PD-L1 Inhibitors by Stage and Molecule Type

DelveInsight’s PD-1 and PD-L1 Inhibitors Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further PD-1 and PD-L1 Inhibitors product details are provided in the report. Download the PD-1 and PD-L1 Inhibitors pipeline report to learn more about the emerging PD-1 and PD-L1 Inhibitors therapies

Some of the key companies in the PD-1 and PD-L1 Inhibitors Therapeutics Market include:

Key companies developing therapies for PD-1 and PD-L1 Inhibitors are – F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, Others.

PD-1 and PD-L1 Inhibitors Pipeline Analysis:

The PD-1 and PD-L1 Inhibitors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 and PD-L1 Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 and PD-L1 Inhibitors Treatment.
• PD-1 and PD-L1 Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PD-1 and PD-L1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 and PD-L1 Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors drugs and therapies

PD-1 and PD-L1 Inhibitors Pipeline Market Drivers

• Rise in prevalence of Cancer, PD-1 and PD-L1 Inhibitors are emerging as an important checkpoint inhibitors used as frontline treatment in various cancer are some of the important factors that are fueling the PD-1 and PD-L1 Inhibitors Market.

PD-1 and PD-L1 Inhibitors Pipeline Market Barriers 

• However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the PD-1 and PD-L1 Inhibitors Market growth.

Scope of PD-1 and PD-L1 Inhibitors Pipeline Drug Insight    

• Coverage: Global
• Key PD-1 and PD-L1 Inhibitors Companies: Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others
• Key PD-1 and PD-L1 Inhibitors Therapies: CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others
• PD-1 and PD-L1 Inhibitors Therapeutic Assessment: PD-1 and PD-L1 Inhibitors current marketed and PD-1 and PD-L1 Inhibitors emerging therapies
• PD-1 and PD-L1 Inhibitors Market Dynamics: PD-1 and PD-L1 Inhibitors market drivers and PD-1 and PD-L1 Inhibitors market barriers 

Request for Sample PDF Report for PD-1 and PD-L1 Inhibitors Commpetitive Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/